Replies to post #323265 on Avid Bioservices Inc (CDMO)

[cjgaddy]

Updated w/Table3, History of Bavi Human Cancer Trials

[patientlywaiting]

Wow! Let's forward that to our new CDMO gang.

[patientlywaiting]

"1-23-18: New Dovepress article by UTSW+PPHM on PS-Targeting"

So here is a good question, is this or will this become news for CDMO?

Do we get a PR on this since we are no longer PPHM a R&D company?

Maybe I'm jumping the gun..............

I need to give them a chance.

[asmarterwookie]

Dove Press is a member of the Open Access Initiative, specializing in peer reviewed Medical Journals. View articles or submit your research for publishing

Open Access Initiative? But why now?

wook

[Thomas517]

Ok am I the only confused one here? What does this mean for us? Is this a joke are we being plunked? What’s the deal? Or the real deal?

[4OurRetirement]

I Wonder If New BOD's Have Seen This???...

since it was originally submitted for review back on Sept 6, 2017

Glta StockHOLDERS!!!

[goodplenty100]

Nice CJ, thanks for posting. Bet you Steve King isn't doing the snow plow in Switzerland! :)

[biopharm]

A little puzzle piece comes together here, where ex Peregrine employee "Nitesh" is working for Informa and in case some forgot:

Ramon

Director, Business Development & Licensing (Peregrine title: Sr. Manager, BD)
Company NamePeregrine Pharmaceuticals
Dates EmployedJun 2010 – Present Employment Duration7 yrs 8 mos
LocationTustin, CA
....
....


Accomplishments:
• Instrumental in establishing a relationship with Dr. Jedd Wolchock and colleagues at MSKCC that led to a research and multiple clinical collaborations in Immunotherapy to validate Peregrine PS targeting immune modulator and identify and develop new targets for immunotherapy.
• Negotiated/finalized clinical agreement w/Astra Zeneca/MedImmune for NSCLC studies involving the combination of bavituximab with PD-L1 inhibitor: Durvalumab

....
....
(Recommendations given by Ramon)

I have had the pleasure of working with Nitesh for a few months in our Bus. Dev. department, where we assigned various oncology focused market research tasks for him to complete.

I have had the opportunity to observe his professional skills as well as interpersonal style. He is consistently pleasant, and takes on all assignments with enthusiasm and dedication.

Regardless of deadlines or other pressures, Nitesh delivered what was asked of him. His superior organizational skills make him the consummate multi-tasker.

...
...

Nitesh Singhvi
Business Intelligence Analyst at Informa

March 19, 2015, Ramon managed Nitesh directly

....
....
https://www.linkedin.com/in/ramon-valencia-ms-38501a9

Nitesh Singhvi

https://www.linkedin.com/in/niteshsinghvi

Now Nitesh also has a recommendation from Ramone and I find that as a nice nugget of info as explained in the past....based on over 500 links for each and with Ramone sealing up those Dr Jedd Wolchok deals etc, combined with DovePress publications .....and the employer to Nitesh = Informa ... and they just merged with DovePress just in Sept 26, 2017, which we see this Peregrine / PS Targeting IP summary submitted also in Sept 2017 ......makes me think how marketing is important !

Funny how so many within Peregrine footsteps like to merge

Informa extends open access position and capability with addition of Dove Medical Press

Open Access expansion…Addition of independent open access (“OA”) publisher, Dove Medical Press, increases Informa’s position and capability in the growing OA market
Quality journal portfolio…Collection of established and indexed journals takes Informa’s OA journal portfolio to over 200 and total number of journals to more than 2,500;
Platform capability…Established platform for identifying new subject categories, managing collaboration and peer review
Attractive fit …Strengthens position in Health Sciences, including growth subjects such as oncology, ophthalmology, neuroscience and psychiatry
London: Informa (LSE: INF.L), the International Exhibitions, Events, Business Intelligence and Academic Publishing Group, today announces the addition of Dove Medical Press, strengthening its capability and presence in open access publishing.

Stephen A. Carter, Informa Group Chief Executive, said: “The addition of Dove Medical Press adds strength and capability to our OA portfolio, further increasing choice and flexibility for researchers across a widening range of subject areas.”

He added: “Its track record, publishing platform and growing reputation in Health Sciences enhance our Journals business, strengthening our position in the attractive and growing OA market.”

Dove Medical Press is an independent OA journals publisher, founded in 2003, producing a range of quality OA journals, mainly in Health Sciences, with additional content in Science and Technology. A large proportion of its journals are indexed by the Web of Science and PubMed and a growing number have established and improving impact factors. Leading titles include OncoTargets and Therapy, International Journal of Nanomedicine and Clinical Ophthalmology.

The addition of Dove Medical Press complements our growing portfolio of OA titles published under the Taylor & Francis and Cogent brands, enabling continued expansion in the attractive OA market. Following the acquisition, Informa will publish more than 200 OA journals, as part of a total journal portfolio of more than 2,500 titles, providing a valuable and growing alternative publishing outlet for authors.

Financial details were not disclosed but the transaction is expected to be modestly accretive to adjusted earnings in the first full year of ownership and deliver a return on investment ahead of the cost of capital within three years.

Media enquiries
Tim Burt / Zoe Watt at Teneo Blue Rubicon on [phone]

Informa Group PLC
Informa is a leading international Business Intelligence, Exhibitions, Events and Academic Publishing Group with annual revenues of over £1.6bn. It helps commercial, professional and academic communities work smarter and make better decisions faster, through specialist content and intelligence, and opportunities to connect and learn.

Dove Medical Press, Ltd
Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum of science, technology and especially medicine. Dove Press was founded in 2003 with the objective of combining the highest editorial standards with the 'best of breed' new publishing technologies. Dove Press has offices in Manchester and London in the United Kingdom, representatives in Princeton, New Jersey in the United States, and editorial offices in Auckland, New Zealand.

https://informa.com/media/press-releases-news/latest-news/informa-extends-open-access-position-and-capability-with-addition-of-dove-medical-press/